Detalhe da pesquisa
1.
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Blood
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518105
2.
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Br J Haematol
; 197(1): 76-81, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34881427
3.
Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study.
Cytometry B Clin Cytom
; 2023 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740440
4.
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.
Cancers (Basel)
; 14(19)2022 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230840
5.
Bispecific antibodies in acute lymphoblastic leukemia therapy.
Expert Rev Hematol
; 13(11): 1211-1233, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33000968
6.
Oxidation-Specific Epitopes (OSEs) Dominate the B Cell Response in Murine Polymicrobial Sepsis.
Front Immunol
; 11: 1570, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32849533
7.
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.
Hemasphere
; 6(8): e754, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35935606